|
|
|
| Rlationship between Platelet Volume Distribution Width, Severity and Prognosis in Patients with Stable Coronary Heart Disease Treated by PCI |
| FENG Mingyue |
| Dandong Central Hospital, Liaoning Dandong 118000, China |
|
|
|
|
Abstract Objective: To explore the relationship between platelet volume distribution width, severity and prognosis in patients with stable coronary heart disease (SCAD) treated by PCI. Methods: From April 2015 to September 2017, 160 patients with stable coronary heart disease treated by PCI in our center were divided into two groups: group A (platelet volume distribution width ≤ 14.2%) and group B (platelet volume distribution width above 14.2%), 80 in each group. The results of angiography and biochemical indexes were collected, and the incidence of adverse events was compared. Results: Compared with patients in group A, the severity of coronary artery stenosis, lesion score and lesion number were significantly lower than those in group B (t=12.819, 6.707, 2.508, P<0.05). In addition, TG, LDL, TC and Cr in group A were significantly lower than those in group B (t=2.305, 4.476, 3.286, 2.741, P<0.05), while HDL was significantly higher than those in group B (t=2.280, P<0.05). In comparison with the prognosis, the incidence of total adverse events in group A was significantly lower than that in group B (χ2 =16.824, P<0.05). Conclusion: The higher the platelet volume distribution width of SCAD patients, the more serious the disease and the more adverse prognosis. And platelet volume distribution width is the sign of platelet activation and reliable. It is recommended that clinicians can be combined with platelet volume distribution width to assess patient's condition and prognosis.
|
|
|
|
|
|
[1] Wang J, Wang J. GW27-e0993 angiographic characteristics of diabetes mellitus(NIDDM) combined with coronary heart disease(CHD) in the clinical observation[J]. Journal of the American College of Cardiology, 2016, 68(16):C107~C108.
[2] Gillette M, Morneau K, Hoang V, et al. Antiplatelet management for coronary heart disease: advances and challenges[J]. Current Atherosclerosis Reports, 2016, 18(6):1~16.
[3] 付光学.冠心病患者血清血小板活化因子的表达及其与冠状动脉斑块性质的关系[J].中国循环杂志,2016,31(7):628~631.
[4] Liu K, Hua B T, Guo T, et al. The assessment of the long-term effects of elective CRT-D of coronary heart disease after PCI.[J]. Eur Rev Med Pharmacol Sci, 2017:21(6):1313~1317.
[5] Bates E R , Tamis-Holland J E , Bittl J A , et al. PCI strategies in patients With ST-Segment elevation myocardial infarction and multivessel coronary artery disease[J]. Journal of the American College of Cardiology, 2016, 68(10):1066~1081.
[6] Choi D H , Kang S H , Song H . Mean platelet volume: a potential biomarker of the risk and prognosis of heart disease[J]. Korean Intern Med, 2016, 31(6):1009~1017.
[7] Higaki T, Kurisu S, Watanabe N, et al. Influence of dual antiplatelet therapy on mean platelet volume in patients with coronary artery disease undergoing percutaneous coronary intervention[J]. Heart & Vessels, 2016, 31(3):269~274.
[8] Yilmaz F, Koklu E, Kizilirmak Y F, et al. Evaluation of mean platelet volume and platelet distribution width in patients with asymptomatic intermediate carotid artery plaque[J]. Kardiologia Polska, 2016, 75(1):35. |
|
|
|
2019, Vol. 25 
